Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern traditional Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly k… Read more
Wecome Pharmaceutical Co Ltd (300878) - Total Assets
Latest total assets as of September 2025: CN¥1.49 Billion CNY
Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) holds total assets worth CN¥1.49 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wecome Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wecome Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wecome Pharmaceutical Co Ltd's total assets of CN¥1.49 Billion consist of 37.3% current assets and 62.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.4% |
| Accounts Receivable | CN¥217.87 Million | 13.2% |
| Inventory | CN¥118.32 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥33.59 Million | 2.0% |
| Goodwill | CN¥10.97 Million | 0.7% |
Asset Composition Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wecome Pharmaceutical Co Ltd's current assets represent 37.3% of total assets in 2024, a decrease from 61.5% in 2013.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, down from 28.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
Wecome Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Wecome Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Wecome Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Wecome Pharmaceutical Co Ltd generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Wecome Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Wecome Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 5.16 | 4.67 |
| Quick Ratio | 1.97 | 4.45 | 4.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥305.01 Million | CN¥ 635.79 Million | CN¥ 784.97 Million |
Wecome Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wecome Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.05 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | CN¥1.65 Billion |
| Market Capitalization | $143.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wecome Pharmaceutical Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wecome Pharmaceutical Co Ltd's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Wecome Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion | -19.27% |
| 2023-12-31 | CN¥2.05 Billion | +6.94% |
| 2022-12-31 | CN¥1.91 Billion | +13.02% |
| 2021-12-31 | CN¥1.69 Billion | +3.96% |
| 2020-12-31 | CN¥1.63 Billion | +85.96% |
| 2019-12-31 | CN¥875.87 Million | +36.62% |
| 2018-12-31 | CN¥641.12 Million | +33.64% |
| 2017-12-31 | CN¥479.74 Million | +52.23% |
| 2016-12-31 | CN¥315.14 Million | +42.03% |
| 2015-12-31 | CN¥221.89 Million | +28.23% |
| 2014-12-31 | CN¥173.04 Million | +61.53% |
| 2013-12-31 | CN¥107.13 Million | -- |